Scholarlink

Abstract <p>Hepatitis B virus (<i>Orthohepadnavirus hominoidei, </i>HBV) is a hepatotropic virus from the <i>Hepadnaviridae</i> family and the causative agent of both acute and chronic hepatitis B (CHB). The possible outcomes of CHB include liver cirrhosis and hepatocellular carcinoma (HCC) that pose a significant burden on the healthcare systems worldwide. In the nuclei of infected hepatocytes of patients with CHB, the HBV genome persists as a pool of covalently closed circular DNA (cccDNA) molecules. Current therapeutic strategies cannot directly target cccDNA. Instead, the available treatments focus on long-term suppression of viral replication and require lifelong administration. Development and evaluation of novel antiviral agents capable of achieving complete HBV eradication require relevant <i>in&#xa0;vivo</i> and <i>in&#xa0;vitro</i> models of HBV infection. Among the available animal models, the following categories are distinguished: (i)&#xa0;animals naturally susceptible to&#xa0;HBV; (ii)&#xa0;surrogate models using animal species susceptible to the related hepadnaviruses; (iii)&#xa0;non-susceptible animals receiving HBV genome via recombinant viral vectors; (iv)&#xa0;models utilizing human hepatocyte xenografts. Among the available <i>in&#xa0;vitro</i> models, primary human and northern treeshrew (<i>Tupaia belangeri</i>) hepatocytes fully support the HBV replication cycle, but they rapidly lose susceptibility to the virus in cell culture. In turn, unmodified human hepatoma cell lines are not susceptible to HBV but can support viral replication after transfection with the viral genome. This review discusses key characteristics, advantages, limitations, and areas of application of the currently available <i>in&#xa0;vivo</i> and <i>in&#xa0;vitro</i> models of HBV infection.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

In vivo and in vitro Models of Hepatitis B Virus Infection

  • 期刊论文

  • 发表日期：

    2025年11月1日

查看全文
  • Yuliya V. Kolyako,
  • Alla S. Zhitkevich,
  • Daria V. Avdoshina,
  • Daria Y. Tanygina,
  • Vasiliy D. Apolokhov,
  • Tatiana V. Gorodnicheva,
  • Dmitry S. Kostyushev,
  • Ekaterina O. Bayurova,
  • Ilya V. Gordeychuk

摘要

Abstract

Hepatitis B virus (Orthohepadnavirus hominoidei, HBV) is a hepatotropic virus from the Hepadnaviridae family and the causative agent of both acute and chronic hepatitis B (CHB). The possible outcomes of CHB include liver cirrhosis and hepatocellular carcinoma (HCC) that pose a significant burden on the healthcare systems worldwide. In the nuclei of infected hepatocytes of patients with CHB, the HBV genome persists as a pool of covalently closed circular DNA (cccDNA) molecules. Current therapeutic strategies cannot directly target cccDNA. Instead, the available treatments focus on long-term suppression of viral replication and require lifelong administration. Development and evaluation of novel antiviral agents capable of achieving complete HBV eradication require relevant in vivo and in vitro models of HBV infection. Among the available animal models, the following categories are distinguished: (i) animals naturally susceptible to HBV; (ii) surrogate models using animal species susceptible to the related hepadnaviruses; (iii) non-susceptible animals receiving HBV genome via recombinant viral vectors; (iv) models utilizing human hepatocyte xenografts. Among the available in vitro models, primary human and northern treeshrew (Tupaia belangeri) hepatocytes fully support the HBV replication cycle, but they rapidly lose susceptibility to the virus in cell culture. In turn, unmodified human hepatoma cell lines are not susceptible to HBV but can support viral replication after transfection with the viral genome. This review discusses key characteristics, advantages, limitations, and areas of application of the currently available in vivo and in vitro models of HBV infection.